These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 30622524)

  • 21. Challenges and new technologies in adoptive cell therapy.
    Zhang P; Zhang G; Wan X
    J Hematol Oncol; 2023 Aug; 16(1):97. PubMed ID: 37596653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer-Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy.
    Starska-Kowarska K
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis.
    Prezzemolo T; Guggino G; La Manna MP; Di Liberto D; Dieli F; Caccamo N
    Front Immunol; 2014; 5():180. PubMed ID: 24795723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promises and challenges of adoptive T-cell therapies for solid tumours.
    Morotti M; Albukhari A; Alsaadi A; Artibani M; Brenton JD; Curbishley SM; Dong T; Dustin ML; Hu Z; McGranahan N; Miller ML; Santana-Gonzalez L; Seymour LW; Shi T; Van Loo P; Yau C; White H; Wietek N; Church DN; Wedge DC; Ahmed AA
    Br J Cancer; 2021 May; 124(11):1759-1776. PubMed ID: 33782566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy.
    Chen Q; Guo X; Ma W
    Oncol Res; 2023; 32(1):49-60. PubMed ID: 38188674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies for Manipulating T Cells in Cancer Immunotherapy.
    Lee HM
    Biomol Ther (Seoul); 2022 Jul; 30(4):299-308. PubMed ID: 35264464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitochondria-Targeting Immunogenic Cell Death Inducer Improves the Adoptive T-Cell Therapy Against Solid Tumor.
    Jiang Q; Zhang C; Wang H; Peng T; Zhang L; Wang Y; Han W; Shi C
    Front Oncol; 2019; 9():1196. PubMed ID: 31781498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
    Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
    Front Immunol; 2020; 11():594556. PubMed ID: 33312177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases-An EAACI position paper of the Task Force on Immunopharmacology (TIPCO).
    Roth-Walter F; Adcock IM; Benito-Villalvilla C; Bianchini R; Bjermer L; Boyman O; Caramori G; Cari L; Fan Chung K; Diamant Z; Eguiluz-Gracia I; Knol EF; Kolios A; Levi-Schaffer F; Nocentini G; Palomares O; Redegeld F; Van Esch B; Stellato C
    Allergy; 2021 Jan; 76(1):90-113. PubMed ID: 32593226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining immunotherapy and targeted therapies in cancer treatment.
    Vanneman M; Dranoff G
    Nat Rev Cancer; 2012 Mar; 12(4):237-51. PubMed ID: 22437869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. External cues to drive B cell function towards immunotherapy.
    Stoycheva D; Simsek H; Weber W; Hauser AE; Klotzsch E
    Acta Biomater; 2021 Oct; 133():222-230. PubMed ID: 33636402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.
    du Plessis N; Kotze LA; Leukes V; Walzl G
    Front Cell Infect Microbiol; 2018; 8():332. PubMed ID: 30298121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials.
    Bender Ignacio RA; Lin LL; Rajdev L; Chiao E
    J Natl Compr Canc Netw; 2018 Aug; 16(8):1018-1026. PubMed ID: 30099376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy of Fungal Infections.
    Datta K; Hamad M
    Immunol Invest; 2015; 44(8):738-76. PubMed ID: 26575463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review.
    Dasgupta S; Gayen S; Chakraborty T; Afrose N; Pal R; Mahata S; Nasare V; Roy S
    Med Oncol; 2024 Mar; 41(5):98. PubMed ID: 38536512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Host-directed immunotherapy of viral and bacterial infections: past, present and future.
    Wallis RS; O'Garra A; Sher A; Wack A
    Nat Rev Immunol; 2023 Feb; 23(2):121-133. PubMed ID: 35672482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.